This Year's Highlights

• GlobeImmune recently raised $38.4 million in Series B financing. The round was led by Lilly Ventures and included HealthCare Ventures, Morgenthaler, Sequel, Medica, Adams Street, PAC-LINK, CIDC, Genentech, Biogen Idec, Yasuda, Partners Healthcare & GC&H
• Initiated a Phase 2 study of GI-4000, a Tarmogen for the treatment of cancers containing ras mutations. It is a double-blind, placebo controlled, multi-center trial evaluating safety, immunogenicity, and efficacy of GI-4000 in early stage pancreas cancer.
• GlobeImmune initiated a Phase 1b study of GI-5005, a Tarmogen for the treatment of chronic HCV infection. The study is a double-blind, placebo controlled, dose-escalation, multi-center trial evaluating the safety, immunogenicity, and efficacy of GI-5005.

Anticipated Highlights

• Topline safety and efficacy data from the Phase 1b trial of GI-5005 mid-2006.
• Topline safety and efficacy data from the Phase 2 trial of GI-4000 in resected pancreas cancer patients 1H 2008
• Filing United States IND's for GI-8000 for avian influenza in early 2007.

Corporate Mission

GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases.

Tarmogens (Targeted Molecular Immunogens) are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein targets that stimulate the immune system against diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, and stimulate cytotoxic T lymphocytes (a.k.a. ?killer T cells?) against cells expressing the desired target. GlobeImmune?s patented Tarmogen platform has a number of advantages over current approaches because Tarmogens generate a potent T cell response, are not neutralized by the host immune system upon repeated administration, do not require a custom vaccine approach and are simple to manufacture.

The Company's lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently starting Phase 2 clinical trials. The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005.